**Supplementary Table 1.** Descriptive characteristics of subjects tested for SARS-CoV-2 with COVID-19-relevant symptoms during the period December 6 to 26, 2021, comparing vaccinated and unvaccinated subjects, Delta cases and SARS-CoV-2-negative controls only

|  | **Unvaccinated, n (%)a** | **2 doses,** **n (%)a** | **SDb** | **3 doses,** **n (%)a** | **SDb** |
| --- | --- | --- | --- | --- | --- |
| **Total** | N=5,932 | N=94,150 |   | N=18,266 |   |
| Subject characteristics |  |  |  |  |  |
| Age (years), mean (standard deviation) | 38.9 ± 15.8 | 40.2 ± 15.3 | 0.09 | 52.6 ± 18.8 | 0.79 |
| Age group (years) |  |  |  |  |  |
| 18–29 | 2,016 (34.0%) | 27,376 (29.1%) | 0.11 | 2,515 (13.8%) | 0.49 |
| 30–39 | 1,637 (27.6%) | 24,615 (26.1%) | 0.03 | 3,076 (16.8%) | 0.26 |
| 40–49 | 902 (15.2%) | 16,612 (17.6%) | 0.07 | 2,344 (12.8%) | 0.07 |
| 50–59 | 645 (10.9%) | 13,457 (14.3%) | 0.10 | 3,272 (17.9%) | 0.20 |
| 60–69 | 423 (7.1%) | 8,188 (8.7%) | 0.06 | 2,948 (16.1%) | 0.28 |
| 70–79 | 199 (3.4%) | 2,738 (2.9%) | 0.03 | 2,718 (14.9%) | 0.41 |
| ≥80 | 110 (1.9%) | 1,164 (1.2%) | 0.05 | 1,393 (7.6%) | 0.27 |
| Male sex | 2,825 (47.6%) | 39,011 (41.4%) | 0.12 | 6,429 (35.2%) | 0.25 |
| Any comorbidityc | 2,396 (40.4%) | 38,250 (40.6%) | 0 | 10,453 (57.2%) | 0.34 |
| Number of SARS-CoV-2 tests within 3 months prior to 14 Dec 2020  |  |  |  |  |  |
| 0 | 4,847 (81.7%) | 69,875 (74.2%) | 0.18 | 12,208 (66.8%) | 0.35 |
| 1 | 825 (13.9%) | 17,984 (19.1%) | 0.14 | 3,666 (20.1%) | 0.16 |
| ≥2 | 260 (4.4%) | 6,291 (6.7%) | 0.10 | 2,392 (13.1%) | 0.31 |
| Receipt of 2019-2020 and/or 2020-2021 influenza vaccination  | 455 (7.7%) | 30,775 (32.7%) | 0.66 | 10,420 (57.0%) | 1.24 |
| Public health unit regiond |  |  |  |  |  |
| Central East | 616 (10.4%) | 7,487 (8.0%) | 0.08 | 1,409 (7.7%) | 0.09 |
| Central West | 1,123 (18.9%) | 17,822 (18.9%) | 0 | 3,110 (17.0%) | 0.05 |
| Durham | 299 (5.0%) | 6,573 (7.0%) | 0.08 | 1,009 (5.5%) | 0.02 |
| Eastern | 325 (5.5%) | 5,707 (6.1%) | 0.02 | 1,234 (6.8%) | 0.05 |
| North | 568 (9.6%) | 5,768 (6.1%) | 0.13 | 1,495 (8.2%) | 0.05 |
| Ottawa | 153 (2.6%) | 4,635 (4.9%) | 0.12 | 1,027 (5.6%) | 0.15 |
| Peel | 649 (10.9%) | 10,922 (11.6%) | 0.02 | 1,547 (8.5%) | 0.08 |
| South West | 1,035 (17.4%) | 10,304 (10.9%) | 0.19 | 2,363 (12.9%) | 0.13 |
| Toronto | 858 (14.5%) | 17,617 (18.7%) | 0.11 | 3,799 (20.8%) | 0.17 |
| York | 267 (4.5%) | 6,941 (7.4%) | 0.12 | 1,206 (6.6%) | 0.09 |
| Household income quintiled, e |  |  |  |  |  |
| 1 (lowest) | 1,418 (23.9%) | 14,532 (15.4%) | 0.21 | 2,441 (13.4%) | 0.27 |
| 2 | 1,295 (21.8%) | 17,245 (18.3%) | 0.09 | 3,027 (16.6%) | 0.13 |
| 3 | 1,179 (19.9%) | 18,816 (20.0%) | 0 | 3,361 (18.4%) | 0.04 |
| 4 | 1,071 (18.1%) | 20,620 (21.9%) | 0.10 | 4,076 (22.3%) | 0.11 |
| 5 (highest) | 922 (15.5%) | 22,528 (23.9%) | 0.21 | 5,270 (28.9%) | 0.32 |
| Essential workers quintiled, f |  |  |  |  |  |
| 1 (0%–32.5%) |   |   |   |   |   |
| 2 (32.5%–42.3%) | 732 (12.3%) | 21,601 (22.9%) | 0.28 | 5,211 (28.5%) | 0.41 |
| 3 (42.3%–49.8%) | 1,042 (17.6%) | 23,401 (24.9%) | 0.18 | 4,573 (25.0%) | 0.18 |
| 4 (50.0%–57.5%) | 1,245 (21.0%) | 18,893 (20.1%) | 0.02 | 3,502 (19.2%) | 0.05 |
| 5 (57.5%–100%) | 1,365 (23.0%) | 16,254 (17.3%) | 0.14 | 2,829 (15.5%) | 0.19 |
| Persons per dwelling quintiled, **g** |  |  |  |  |  |
| 1 (0–2.1) | 1,120 (18.9%) | 17,004 (18.1%) | 0.02 | 3,770 (20.6%) | 0.04 |
| 2 (2.2–2.4) | 1,261 (21.3%) | 15,453 (16.4%) | 0.12 | 3,192 (17.5%) | 0.10 |
| 3 (2.5–2.6) | 833 (14.0%) | 12,429 (13.2%) | 0.02 | 2,512 (13.8%) | 0.01 |
| 4 (2.7–3.0) | 1,424 (24.0%) | 23,016 (24.4%) | 0.01 | 4,439 (24.3%) | 0.01 |
| 5 (3.1–5.7) | 1,210 (20.4%) | 25,632 (27.2%) | 0.16 | 4,206 (23.0%) | 0.06 |
| Self-identified visible minority quintiled, h |  |  |  |  |  |
| 1 (0.0%–2.2%) | 1,225 (20.7%) | 13,526 (14.4%) | 0.17 | 2,958 (16.2%) | 0.12 |
| 2 (2.2%–7.5%) | 1,186 (20.0%) | 16,549 (17.6%) | 0.06 | 3,441 (18.8%) | 0.03 |
| 3 (7.5%–18.7%) | 1,052 (17.7%) | 18,445 (19.6%) | 0.05 | 3,921 (21.5%) | 0.09 |
| 4 (18.7%–43.5%) | 1,139 (19.2%) | 21,562 (22.9%) | 0.09 | 4,157 (22.8%) | 0.09 |
| 5 (43.5%–100%) | 1,251 (21.1%) | 23,495 (25.0%) | 0.09 | 3,645 (20.0%) | 0.03 |
| Week of test |  |  |  |  |  |
| 6 Dec 2021 to 12 Dec 2021 | 1,999 (33.7%) | 27,997 (29.7%) | 0.09 | 2,551 (14.0%) | 0.48 |
| 13 Dec 2021 to 19 Dec 2021 | 2,152 (36.3%) | 35,471 (37.7%) | 0.03 | 5,297 (29.0%) | 0.16 |
| 20 Dec 2021 to 26 Dec 2021 | 1,781 (30.0%) | 30,682 (32.6%) | 0.06 | 10,418 (57.0%) | 0.57 |
| Prior positive SARS-CoV-2 test | 253 (4.3%) | 3,568 (3.8%) | 0.02 | 446 (2.4%) | 0.10 |
| COVID-19 vaccine characteristics |  |  |  |  |  |
| Unvaccinated | 5,932 (100%) | n/a |  | n/a |  |
| Received 2-dose primary series only (with at least 1 mRNA vaccine) | n/a | 94,150 (100%) |  | n/a |  |
| Received BNT162b2 for third dose | n/a | n/a |  | 14,916 (81.7%) |  |
| Received mRNA-1273 for third dose | n/a | n/a |  | 3,350 (18.3%) |  |
| Time since second dose |  |  |  |  |  |
| 7-59 days | n/a | 2,315 (2.5%) |  | n/a |  |
| 60-119 days | n/a | 6,954 (7.4%) |  | n/a |  |
| 120-179 days | n/a | 62,577 (66.5%) |  | n/a |  |
| 180-239 days | n/a | 20,509 (21.8%) |  | n/a |  |
| ≥240 days | n/a | 1,795 (1.9%) |  | n/a |  |
| Time since third dose |  |  |  |  |  |
| 0-6 days | n/a | n/a |  | 6,037 (33.1%) |  |
| 7-59 days | n/a | n/a |  | 11,357 (62.2%) |  |
| ≥60 days | n/a | n/a |  | 872 (4.8%) |  |
| Interval between first and second doses |  |  |  |  |  |
| 15-34 days | n/a | 12,675 (13.5%) |  | 3,224 (17.7%) |  |
| 35-55 days | n/a | 34,995 (37.2%) |  | 3,965 (21.7%) |  |
| ≥56 days | n/a | 46,480 (49.4%) |  | 11,077 (60.6%) |  |
| Interval between second and third doses |  |  |  |  |  |
| ≤111 days | n/a | n/a |  | 240 (1.3%) |  |
| 112-167 days | n/a | n/a |  | 1,643 (9.0%) |  |
| ≥168 days | n/a | n/a |  | 16,383 (89.7%) |  |

**a**Proportion reported, unless stated otherwise.

**b**SD=standardized difference. Standardized differences of >0.10 are considered clinically relevant. Comparison of subjects who have received 2 doses with unvaccinated subjects, and subjects who have received 3 doses with unvaccinated subjects.

cComorbidities include chronic respiratory diseases, chronic heart diseases, hypertension, diabetes, immunocompromising conditions due to underlying diseases or therapy, autoimmune diseases, chronic kidney disease, advanced liver disease, dementia/frailty and history of stroke or transient ischemic attack.

dThe sum of counts does not equal the column total because of individuals with missing information (<1.0%) for this characteristic.

eHousehold income quintile has variable cut-off values in each city/Census area to account for cost of living. A dissemination area (DA) being in quintile 1 means it is among the lowest 20% of DAs in its city by income.

fPercentage of people in the area working in the following occupations: sales and service occupations; trades, transport and equipment operators and related occupations; natural resources, agriculture, and related production occupations; and occupations in manufacturing and utilities. Census counts for people are randomly rounded up or down to the nearest number divisible by 5, which causes some minor imprecision.

**g**Range of persons per dwelling.

hPercentage of people in the area who self-identified as a visible minority. Census counts for people are randomly rounded up or down to the nearest number divisible by 5, which causes some minor imprecision.

**Supplementary Table 2.** Characteristics of subjects tested for SARS-CoV-2 with COVID-19-relevant symptoms during the period November 22 to December 26, 2021, comparing Omicron cases and SARS-CoV-2-negative controls by time period

|  | **SARS-CoV-2 negative,****22 Nov to** **12 Dec 2021,** **n (%)a** | **Omicron,** **22 Nov to** **12 Dec 2021,** **n (%)a** | **SDb** | **SARS-CoV-2 negative,** **13 Dec to** **19 Dec 2021,** **n (%)a** | **Omicron,****13 Dec to** **19 Dec 2021,** **n (%)a** | **SDb** | **SARS-CoV-2 negative,** **20 Dec to** **26 Dec 2021,** **n (%)a** | **Omicron,****20 Dec to** **26 Dec 2021,** **n (%)a** | **SDb** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Total** | N=83,111 | N=776 |   | N=41,090 | N=5,049 |   | N=41,894 | N=10,309 |   |
| Subject characteristics |  |  |  |  |  |  |  |  |  |
| Age (years), mean (standard deviation) | 41.9 ± 16.5 | 32.2 ± 14.0 | 0.63 | 42.0 ± 16.4 | 36.2 ± 13.8 | 0.39 | 42.1 ± 16.7 | 36.3 ± 14.2 | 0.38 |
| Age group (years) |  |  |  |  |  |  |  |  |  |
| 18–29 | 22,039 (26.5%) | 424 (54.6%) | 0.60 | 10,941 (26.6%) | 2,071 (41.0%) | 0.31 | 11,820 (28.2%) | 4,341 (42.1%) | 0.29 |
| 30–39 | 21,572 (26.0%) | 135 (17.4%) | 0.21 | 10,308 (25.1%) | 1,141 (22.6%) | 0.06 | 9,999 (23.9%) | 2,201 (21.4%) | 0.06 |
| 40–49 | 14,239 (17.1%) | 114 (14.7%) | 0.07 | 7,171 (17.5%) | 948 (18.8%) | 0.03 | 6,473 (15.5%) | 1,767 (17.1%) | 0.05 |
| 50–59 | 11,676 (14.0%) | 71 (9.1%) | 0.15 | 5,879 (14.3%) | 573 (11.3%) | 0.09 | 6,429 (15.3%) | 1,282 (12.4%) | 0.08 |
| 60–69 | 7,789 (9.4%) | 17 (2.2%) | 0.31 | 3,995 (9.7%) | 215 (4.3%) | 0.22 | 4,187 (10.0%) | 492 (4.8%) | 0.20 |
| 70–79 | 3,827 (4.6%) | 10-14 (1.3-1.8%) | 0.16-0.20 | 1,922 (4.7%) | 64 (1.3%) | 0.20 | 2,018 (4.8%) | 160 (1.6%) | 0.19 |
| ≥80 | 1,969 (2.4%) | ≤5 (≤0.6%) | 0.14-0.20 | 874 (2.1%) | 37 (0.7%) | 0.12 | 968 (2.3%) | 66 (0.6%) | 0.14 |
| Male sex | 33,648 (40.5%) | 348 (44.8%) | 0.09 | 16,779 (40.8%) | 2,553 (50.6%) | 0.20 | 16,769 (40.0%) | 4,956 (48.1%) | 0.16 |
| Any comorbidityc | 36,661 (44.1%) | 264 (34.0%) | 0.21 | 17,565 (42.7%) | 1,852 (36.7%) | 0.12 | 18,105 (43.2%) | 3,744 (36.3%) | 0.14 |
| Number of SARS-CoV-2 tests within 3 months prior to 14 Dec 2020  |  |  |  |  |  |  |  |  |  |
| 0 | 60,255 (72.5%) | 558 (71.9%) | 0.01 | 29,981 (73.0%) | 3,880 (76.8%) | 0.09 | 30,847 (73.6%) | 8,043 (78.0%) | 0.10 |
| 1 | 16,139 (19.4%) | 158 (20.4%) | 0.02 | 7,972 (19.4%) | 912 (18.1%) | 0.03 | 7,883 (18.8%) | 1,720 (16.7%) | 0.06 |
| ≥2 | 6,717 (8.1%) | 60 (7.7%) | 0.01 | 3,137 (7.6%) | 257 (5.1%) | 0.10 | 3,164 (7.6%) | 546 (5.3%) | 0.09 |
| Receipt of 2019-2020 and/or 2020-2021 influenza vaccination  | 28,656 (34.5%) | 195 (25.1%) | 0.21 | 14,832 (36.1%) | 1,312 (26.0%) | 0.22 | 14,942 (35.7%) | 2,516 (24.4%) | 0.25 |
| Public health unit regiond |  |  |  |  |  |  |  |  |  |
| Central East | 7,677 (9.2%) | 25 (3.2%) | 0.25 | 3,473 (8.5%) | 275 (5.4%) | 0.12 | 2,904 (6.9%) | 532 (5.2%) | 0.07 |
| Central West | 14,860 (17.9%) | 156 (20.1%) | 0.06 | 7,905 (19.2%) | 1,149 (22.8%) | 0.09 | 8,004 (19.1%) | 2,605 (25.3%) | 0.15 |
| Durham | 5,980 (7.2%) | 44 (5.7%) | 0.06 | 2,688 (6.5%) | 337 (6.7%) | 0.01 | 2,647 (6.3%) | 670 (6.5%) | 0.01 |
| Eastern | 5,524 (6.6%) | 151 (19.5%) | 0.39 | 2,747 (6.7%) | 317 (6.3%) | 0.02 | 2,185 (5.2%) | 405 (3.9%) | 0.06 |
| North | 6,529 (7.9%) | <=5 (0.6%) | 0.36 | 2,530 (6.2%) | 64 (1.3%) | 0.26 | 2,769 (6.6%) | 199 (1.9%) | 0.23 |
| Ottawa | 3,221 (3.9%) | 78 (10.1%) | 0.24 | 1,974 (4.8%) | 380 (7.5%) | 0.11 | 2,365 (5.6%) | 527 (5.1%) | 0.02 |
| Peel | 9,363 (11.3%) | 86 (11.1%) | 0.01 | 4,439 (10.8%) | 740 (14.7%) | 0.12 | 4,733 (11.3%) | 1,728 (16.8%) | 0.16 |
| South West | 9,103 (11.0%) | 28 (3.6%) | 0.29 | 4,568 (11.1%) | 201 (4.0%) | 0.27 | 4,677 (11.2%) | 770 (7.5%) | 0.13 |
| Toronto | 14,433 (17.4%) | 148 (19.1%) | 0.04 | 7,778 (18.9%) | 1,143 (22.6%) | 0.09 | 8,301 (19.8%) | 1,820 (17.7%) | 0.06 |
| York | 6,069 (7.3%) | 51 (6.6%) | 0.03 | 2,810 (6.8%) | 413 (8.2%) | 0.05 | 3,158 (7.5%) | 1,012 (9.8%) | 0.08 |
| Household income quintiled, e |  |  |  |  |  |  |  |  |  |
| 1 (lowest) | 13,798 (16.6%) | 71 (9.1%) | 0.22 | 6,255 (15.2%) | 605 (12.0%) | 0.09 | 6,248 (14.9%) | 1,239 (12.0%) | 0.08 |
| 2 | 15,485 (18.6%) | 105 (13.5%) | 0.14 | 7,531 (18.3%) | 787 (15.6%) | 0.07 | 7,574 (18.1%) | 1,643 (15.9%) | 0.06 |
| 3 | 16,421 (19.8%) | 125 (16.1%) | 0.10 | 8,007 (19.5%) | 914 (18.1%) | 0.04 | 8,428 (20.1%) | 2,056 (19.9%) | 0 |
| 4 | 17,977 (21.6%) | 194 (25.0%) | 0.08 | 8,806 (21.4%) | 1,139 (22.6%) | 0.03 | 9,302 (22.2%) | 2,456 (23.8%) | 0.04 |
| 5 (highest) | 19,016 (22.9%) | 275 (35.4%) | 0.28 | 10,301 (25.1%) | 1,572 (31.1%) | 0.14 | 10,170 (24.3%) | 2,871 (27.8%) | 0.08 |
| Essential workers quintiled, f |  |  |  |  |  |  |  |  |  |
| 1 (0%–32.5%) | 17,484 (21.0%) | 286 (36.9%) | 0.35 | 9,811 (23.9%) | 1,585 (31.4%) | 0.17 | 10,231 (24.4%) | 2,684 (26.0%) | 0.04 |
| 2 (32.5%–42.3%) | 19,900 (23.9%) | 252 (32.5%) | 0.19 | 10,140 (24.7%) | 1,299 (25.7%) | 0.02 | 10,398 (24.8%) | 2,952 (28.6%) | 0.09 |
| 3 (42.3%–49.8%) | 16,962 (20.4%) | 111 (14.3%) | 0.16 | 7,978 (19.4%) | 953 (18.9%) | 0.01 | 8,478 (20.2%) | 2,001 (19.4%) | 0.02 |
| 4 (50.0%–57.5%) | 15,110 (18.2%) | 80 (10.3%) | 0.23 | 7,200 (17.5%) | 696 (13.8%) | 0.10 | 6,865 (16.4%) | 1,500 (14.6%) | 0.05 |
| 5 (57.5%–100%) | 12,986 (15.6%) | 41 (5.3%) | 0.34 | 5,702 (13.9%) | 479 (9.5%) | 0.14 | 5,678 (13.6%) | 1,104 (10.7%) | 0.09 |
| Persons per dwelling quintiled, **g** |  |  |  |  |  |  |  |  |  |
| 1 (0–2.1) | 15,056 (18.1%) | 110 (14.2%) | 0.11 | 7,726 (18.8%) | 790 (15.6%) | 0.08 | 7,833 (18.7%) | 1,630 (15.8%) | 0.08 |
| 2 (2.2–2.4) | 14,188 (17.1%) | 115 (14.8%) | 0.06 | 6,910 (16.8%) | 587 (11.6%) | 0.15 | 6,978 (16.7%) | 1,244 (12.1%) | 0.13 |
| 3 (2.5–2.6) | 11,086 (13.3%) | 97 (12.5%) | 0.03 | 5,424 (13.2%) | 631 (12.5%) | 0.02 | 5,552 (13.3%) | 1,196 (11.6%) | 0.05 |
| 4 (2.7–3.0) | 20,230 (24.3%) | 199 (25.6%) | 0.03 | 10,152 (24.7%) | 1,364 (27.0%) | 0.05 | 10,111 (24.1%) | 2,589 (25.1%) | 0.02 |
| 5 (3.1–5.7) | 21,849 (26.3%) | 247 (31.8%) | 0.12 | 10,605 (25.8%) | 1,637 (32.4%) | 0.15 | 11,155 (26.6%) | 3,573 (34.7%) | 0.17 |
| Self-identified visible minority quintiled, h |  |  |  |  |  |  |  |  |  |
| 1 (0.0%–2.2%) | 13,212 (15.9%) | 92 (11.9%) | 0.12 | 6,166 (15.0%) | 416 (8.2%) | 0.21 | 5,992 (14.3%) | 937 (9.1%) | 0.16 |
| 2 (2.2%–7.5%) | 15,331 (18.4%) | 116 (14.9%) | 0.09 | 7,418 (18.1%) | 709 (14.0%) | 0.11 | 7,047 (16.8%) | 1,420 (13.8%) | 0.08 |
| 3 (7.5%–18.7%) | 16,103 (19.4%) | 201 (25.9%) | 0.16 | 8,337 (20.3%) | 1,091 (21.6%) | 0.03 | 8,142 (19.4%) | 2,123 (20.6%) | 0.03 |
| 4 (18.7%–43.5%) | 17,816 (21.4%) | 190 (24.5%) | 0.07 | 9,287 (22.6%) | 1,392 (27.6%) | 0.11 | 10,013 (23.9%) | 2,680 (26.0%) | 0.05 |
| 5 (43.5%–100%) | 19,984 (24.0%) | 171 (22.0%) | 0.05 | 9,623 (23.4%) | 1,404 (27.8%) | 0.10 | 10,457 (25.0%) | 3,081 (29.9%) | 0.11 |
| Prior positive SARS-CoV-2 test | 3,418 (4.1%) | 9 (1.2%) | 0.19 | 1,462 (3.6%) | 42 (0.8%) | 0.19 | 1,520 (3.6%) | 66 (0.6%) | 0.21 |
| COVID-19 vaccine characteristics |  |  |  |  |  |  |  |  |  |
| Unvaccinated | 4,453 (5.4%) | 35 (4.5%) | 0.04 | 1,605 (3.9%) | 236 (4.7%) | 0.04 | 1,524 (3.6%) | 526 (5.1%) | 0.07 |
| Received 2-dose primary series only (with at least 1 mRNA vaccine) | 73,350 (88.3%) | 722 (93.0%) | 0.16 | 34,255 (83.4%) | 4,525 (89.6%) | 0.18 | 30,019 (71.7%) | 8,605 (83.5%) | 0.29 |
| Received BNT162b2 for third dose | 4,524 (5.4%) | 14-18 (1.8-2.3%) | 0.16-0.20 | 4,403 (10.7%) | 255 (5.1%) | 0.21 | 8,209 (19.6%) | 953 (9.2%) | 0.30 |
| Received mRNA-1273 for third dose | 784 (0.9%) | ≤5 (≤0.6%) | 0.03-0.11 | 827 (2.0%) | 33 (0.7%) | 0.12 | 2,142 (5.1%) | 225 (2.2%) | 0.16 |
| Time since second dose |  |  |  |  |  |  |  |  |  |
| 7-59 days | 2,631 (3.2%) | 16 (2.1%) | 0.07 | 815 (2.0%) | 75 (1.5%) | 0.04 | 640 (1.5%) | 141 (1.4%) | 0.01 |
| 60-119 days | 7,063 (8.5%) | 49 (6.3%) | 0.08 | 2,394 (5.8%) | 313 (6.2%) | 0.02 | 2,085 (5.0%) | 645 (6.3%) | 0.06 |
| 120-179 days | 56,227 (67.7%) | 561 (72.3%) | 0.10 | 23,162 (56.4%) | 3,036 (60.1%) | 0.08 | 17,369 (41.5%) | 4,975 (48.3%) | 0.14 |
| 180-239 days | 5,810 (7.0%) | 81 (10.4%) | 0.12 | 7,242 (17.6%) | 1,044 (20.7%) | 0.08 | 9,380 (22.4%) | 2,695 (26.1%) | 0.09 |
| ≥240 days | 1,619 (1.9%) | 15 (1.9%) | 0 | 642 (1.6%) | 57 (1.1%) | 0.04 | 545 (1.3%) | 149 (1.4%) | 0.01 |
| Time since third dose |  |  |  |  |  |  |  |  |  |
| No third dose (i.e., only 2 doses) | 73,350 (88.3%) | 722 (93.0%) | 0.16 | 34,255 (83.4%) | 4,525 (89.6%) | 0.18 | 30,019 (71.7%) | 8,605 (83.5%) | 0.29 |
| 0-6 days | 1,040 (1.3%) | 6 (0.8%) | 0.05 | 1,405 (3.4%) | 127 (2.5%) | 0.05 | 4,127 (9.9%) | 672 (6.5%) | 0.12 |
| 7-59 days | 3,845 (4.6%) | 8-12 (1.0-1.5%) | 0.18-0.22 | 3,528 (8.6%) | 152 (3.0%) | 0.24 | 5,844 (13.9%) | 474 (4.6%) | 0.33 |
| ≥60 days | 423 (0.5%) | ≤5 (0.1%) | 0.02-0.07 | 297 (0.7%) | 9 (0.2%) | 0.08 | 380 (0.9%) | 32 (0.3%) | 0.08 |
| Interval between first dose and second dose |  |  |  |  |  |  |  |  |  |
| 15-34 days | 11,776 (14.2%) | 159 (20.5%) | 0.17 | 5,538 (13.5%) | 705 (14.0%) | 0.01 | 5,591 (13.3%) | 1,418 (13.8%) | 0.01 |
| 35-55 days | 26,518 (31.9%) | 323 (41.6%) | 0.20 | 13,760 (33.5%) | 1,978 (39.2%) | 0.12 | 14,167 (33.8%) | 3,871 (37.5%) | 0.08 |
| ≥56 days | 40,364 (48.6%) | 259 (33.4%) | 0.31 | 20,187 (49.1%) | 2,130 (42.2%) | 0.14 | 20,612 (49.2%) | 4,494 (43.6%) | 0.11 |
| Interval between second dose and third dose |  |  |  |  |  |  |  |  |  |
| No third dose (i.e., only 2 doses) | 73,350 (88.3%) | 722 (93.0%) | 0.16 | 34,255 (83.4%) | 4,525 (89.6%) | 0.18 | 30,019 (71.7%) | 8,605 (83.5%) | 0.29 |
| ≤111 days | 177 (0.2%) | ≤5 (0.1%) | 0.02 | 83 (0.2%) | 7 (0.1%) | 0.02 | 88 (0.2%) | 10 (0.1%) | 0.03 |
| 112-167 days | 690 (0.8%) | ≤5 (0.1%) | 0.10 | 475 (1.2%) | 10 (0.2%) | 0.12 | 853 (2.0%) | 111 (1.1%) | 0.08 |
| ≥168 days | 4,441 (5.3%) | 14-18 (1.8-2.3%) | 0.15-0.19 | 4,672 (11.4%) | 271 (5.4%) | 0.22 | 9,410 (22.5%) | 1,057 (10.3%) | 0.33 |

**a**Proportion reported, unless stated otherwise.

**b**SD=standardized difference. Standardized differences of >0.10 are considered clinically relevant. Comparison of Omicron-positive cases with SARS-CoV-2-negative controls in each time period.

cComorbidities include chronic respiratory diseases, chronic heart diseases, hypertension, diabetes, immunocompromising conditions due to underlying diseases or therapy, autoimmune diseases, chronic kidney disease, advanced liver disease, dementia/frailty and history of stroke or transient ischemic attack.

dThe sum of counts does not equal the column total because of individuals with missing information (<1.0%) for this characteristic.

eHousehold income quintile has variable cut-off values in each city/Census area to account for cost of living. A dissemination area (DA) being in quintile 1 means it is among the lowest 20% of DAs in its city by income.

fPercentage of people in the area working in the following occupations: sales and service occupations; trades, transport and equipment operators and related occupations; natural resources, agriculture, and related production occupations; and occupations in manufacturing and utilities. Census counts for people are randomly rounded up or down to the nearest number divisible by 5, which causes some minor imprecision.

**g**Range of persons per dwelling.

hPercentage of people in the area who self-identified as a visible minority. Census counts for people are randomly rounded up or down to the nearest number divisible by 5, which causes some minor imprecision.

**Supplementary Table 3.** Number of Omicron and Delta severe outcomes (hospitalization or death) by laboratory testing categorization during the period December 6 to 26, 2021

|  |  |  |  |
| --- | --- | --- | --- |
| **Classification criteria** | **6 Dec to 12 Dec 2021** | **13 Dec to 19 Dec 2021** | **20 Dec to 26 Dec 2021** |
| Omicron confirmed via WGS or SGTF | 7 | 28 | 53 |
| Omicron classified if collection date ≥ 21 December 2021 and no or inconclusive SGTF results | n/a | n/a | 177 |
| Delta confirmed via WGS or SGTF | 121 | 115 | 61 |
| No classification (excluded) | 62 | 65 | 15 |

WGS: whole genome sequencing; SGTF: S-gene target failure

**Supplementary Table 4.** Estimates of vaccine effectiveness\* against severe outcomes (hospitalization or death) during the period December 6 to 26, 2021 using the less specific definition of Omicron and Delta

| **Outcome** | **Doses** | **Vaccine products** | **Days since latest dose** | **Vaccine effectiveness against Omicron (95% CI)** |
| --- | --- | --- | --- | --- |
| Severe outcomes | First 2 doses | ≥1 mRNA vaccine | 7-59 | 89 (64, 97) |
|  |  |  | 60-119 | 85 (69, 92) |
|  |  |  | 120-179 | 92 (89, 95) |
|  |  |  | 180-239 | 93 (89, 95) |
|  |  |  | ≥240 | 93 (77, 98) |
|  | Third dose | Any mRNA vaccine | 0-6 | 94 (90, 96) |
|  |  |  | ≥7 | 98 (97, 99) |
|  |  | BNT162b2 | 0-6 | 95 (91, 97) |
|  |  |  | ≥7 | 98 (97, 99) |
|  |  | mRNA-1273 | 0-6 | 91 (81, 96) |
|  |  |  | ≥7 | 98 (96, 99) |

\*Vaccine effectiveness estimates adjusted for: age (in 10-year age bands), sex, public health unit region of residence, number of SARS-CoV-2 PCR tests during the 3 months prior to December 14, 2020, past SARS-CoV-2 infection >90 days prior to index date, comorbidities, influenza vaccination status during the 2019/2020 and/or 2020/2021 influenza seasons, and neighbourhood-level information on median household income, proportion of the working population employed as non-health essential workers, mean number of persons per dwelling, and proportion of the population who self-identify as a visible minority.

**Supplementary Figure 1.** Estimates of vaccine effectiveness against any infection (irrespective of symptoms or severity) with Omicron or Delta, comparing results reported in an initial pre-print using an earlier time period (November 22 to December 19, 2021; panel A) to an updated time period (December 6 to 26, 2021; panel B). The second period excluded the first two weeks (with only 47 Omicron cases) and added an additional week. Panel A included individuals with whole genome sequencing (WGS) or S-gene target failure (SGTF) results, as well as those with missing or inconclusive SGTF results prior to December 3, 2021 (when the prevalence of Omicron was <5% in the province), whereas panel B was restricted to WGS or SGTF results. Biases introduced by differential access or test-seeking behaviour by exposure or vaccination status persisted over time when using any infection as the outcome, reinforcing the importance of using symptomatic infection as a more appropriate outcome for estimating vaccine effectiveness.

